This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Heseltine, P. N. R. Articles by Finegold, S. M. Search for Related Content PubMed PubMed Citation Articles by Heseltine, P. N. R. Articles by Finegold, S. M.

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1977 March; 11(3): 427-434
Copyright © 1977 American Society for Microbiology. All Rights Reserved.

Cefoxitin: Clinical Evaluation in Thirty-Eight Patients

Infectious Disease Section, Medical Service, Wadsworth Hospital Center, Veterans Administration, Los Angeles, California 90073
Department of Medicine, UCLA School of Medicine, Los Angeles, California 90024

ABSTRACT

Clinical and bacteriological efficacy, patient tolerance, and toxicity of cefoxitin, a beta-lactamase-resistant cephamycin, were evaluated in 38 patients; 13 had soft tissue infection, 12 had pneumonia, 3 had urinary tract infection, 2 had peritonitis, and 4 had miscellaneous infections. In five patients, infection was clinically evident, though not bacteriologically proven. The latter patients were evaluated with regard to tolerance and toxicity only. Among the 34 infections in 33 patients, 71% were considered clinically cured; 86% of those patients who could be recultured were bacteriologically cured. Phlebitis was noted in 32% of the total group, and eosinophilia was observed in 16%. Unexplained deterioration in renal function occurred in two patients. Mean peak cefoxitin levels in serum were 72 µg/ml 30 min after a 2-g infusion and 32 µg/ml 30 min after a 1-g infusion. Cefoxitin was more active against facultatively and obligately anaerobic gram-negative organisms isolated from these patients than was cephalothin.